LONDON, UK, March 27, 2020 / B3C newswire / -- Immune Regulation Ltd, a clinical stage biotech company, today announces the appointment of Jonathan Rigby as CEO and a member of the Board of Directors.
Based in the U.S., Jonathan is an experienced CEO with three productive decades of pharmaceutical, biotech and drug delivery technology value creating achievements. In 2011 he became the CEO of SteadyMed Therapeutics Inc. and focused the company on the development of drug device combination products to treat Pulmonary Hypertension. He led the company through a Nasdaq listing in 2015 (Nasdaq: STDY) and a public-to-public company sale to United Therapeutics (Nasdaq: UTHR) in late 2018.
In 2006 he cofounded Zogenix, Inc. (Nasdaq: ZGNX) a specialty pharmaceutical company now focused on the development and commercialization of drug products to treat rare diseases and was instrumental in its listing on Nasdaq in 2010. Earlier in his career, Jonathan held commercial and business development positions of increasing responsibility at large pharmaceutical companies including Merck and Bristol Myers Squibb and Profile Therapeutics, now Phillips Medical.
Dr. Dominik Escher, Chairman of Immune Regulation said: “We are excited to welcome Jonathan at Immune Regulation. He brings a wealth of experience across many areas of the pharmaceutical industry that are relevant to the prosperity of Immune Regulation. I am confident that he is the ideal candidate to lead the next stage of clinical development of our two key therapies in immune system resetting. I would like also to thank Richard Nagle, our outgoing Chief Executive, for his leadership of the business since 2017."
Jonathan Rigby said: “I am delighted to be joining the very talented team at Immune Regulation. The Company has first-in-class immune-resetting therapies with a broad potential to treat autoimmune diseases. For example, IRL201805 and IRL201104 have shown considerable efficacy in preclinical and human clinical studies in rheumatoid arthritis and asthma / severe allergy respectively. We are also in the early stages of assessing the potential of IRL1104 to reduce lung inflammation which may be a consequence in patients infected by the COVID-19 virus.”